Clinical Trial Update: Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating besifloxacin ophthalmic suspension 0.6% for bacterial conjunctivitis was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• Besifloxacin ophthalmic suspension 0.6% (besifloxacin)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Bacterial Conjunctivitis | Phase 3 | Status: TERMINATED | Results posted: 2014-09-17